Clinical trial

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518

Study summary

ClinicalTrials.gov

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Pembrolizumab Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention MK-4830 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Belzutifan Normalized identity: belzutifan View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Lenvatinib Normalized identity: lenvatinib View linked drug · Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Pembrolizumab/Quavonlimab Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Favezelimab/Pembrolizumab Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-12-17

PhasePHASE1 / PHASE2

Conditions

Carcinoma, Renal Cellunresolved

Interventions

PembrolizumabBIOLOGICAL

MK-4830BIOLOGICAL

BelzutifanDRUG · verified · RxNorm: belzutifan

LenvatinibDRUG · verified · RxNorm: lenvatinib

Pembrolizumab/QuavonlimabBIOLOGICAL

Favezelimab/PembrolizumabBIOLOGICAL

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

New YorkNew York, United States2 SeoulSouth Korea2 SantiagoRegion M. de Santiago, Chile2 ChicagoIllinois, United States1 DallasTexas, United States1 TorontoOntario, Canada1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 MadridSpain1 PittsburghPennsylvania, United States1 MontrealQuebec, Canada1 DurhamNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04626518 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.